The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing primary percutaneous intervention and receiving abciximab [PDF]
Cardiology JournalBACKGROUND: Our study compared the effect of P2Y12 receptor inhibitors in combination with abciximab on clinical outcomes in patients with acute coronary syndrome (ACS).
Onur Altınkaya +9 more
doaj +4 more sources
Therapeutics and Clinical Risk Management, 2014 Artur Dziewierz,1 Tomasz Rakowski,1 Dariusz Dudek2 12nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland; 2Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland Abstract ...
Dziewierz A, Rakowski T, Dudek D
doaj +4 more sources
Abciximab in rescue therapy of thromboembolic events during endovascular treatment of cerebral aneurysms: single center experience of 49 cases [PDF]
Frontiers in NeurologyBackgroundThe aim of this study was to assess the safety and effectiveness of abciximab (ReoPro®), a glycoprotein-IIb/IIIa receptor antagonist, in the management of thromboembolic complications during endovascular treatment of intracranial aneurysms ...
Lukas Lenhart +7 more
doaj +2 more sources
Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s) [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Thrombocytopenia is a rare but serious complication of the intravenous glycoprotein IIb/IIIa (GPIIb/IIIa; integrin αIIbβ3) receptor inhibitors (GPIs), abciximab, eptifibatide, and tirofiban. The thrombocytopenia ranges from mild (50 000–100 000 platelets/
Sem A. O. F. Rikken +4 more
doaj +2 more sources
Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
Vascular Health and Risk Management, 2010 Jennifer Vergara-Jimenez, Pierluigi TricociDepartment of Medicine-Cardiology, Duke Clinical Research Institute, Durham, North Carolina, USAAbstract: Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients ...
Jennifer Vergara-Jimenez +1 more
doaj +3 more sources
Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion [PDF]
, 2002 BACKGROUND: GPIIb/IIIa inhibitors abciximab and eptifibatide have been shown to inhibit platelet aggregation in ischemic heart disease. Our aim was to test the efficacy of abiciximab (Reo Pro) or eptifibatide (Integrilin) alone or in combination with ...
Bertuglia, Silva, Giusti, Andrea
core +4 more sources
Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration [PDF]
Trials, 2009 Background Administration of abciximab during primary percutaneous coronary intervention is an effective adjunctive therapy in the treatment of patients with ST-segment elevation myocardial infarction.
Gu Youlan L +6 more
doaj +2 more sources
Endo-chip laser-induced thrombus formation: a vessel-on-chip model for in vitro testing of antithrombotic agents [PDF]
Blood Vessels, Thrombosis & Hemostasis: Mouse models, such as the intravital laser-induced model of thrombus formation, are commonly used for mechanistic and preclinical studies in thrombosis. However, their translational value is limited by species differences.
Alexander Dupuy +7 more
doaj +2 more sources
Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. [PDF]
, 1999 BACKGROUND: In patients with refractory unstable angina, the platelet glycoprotein IIb/IIIa-receptor antibody abciximab reduces the incidence of cardiac events before and during coronary angioplasty.
Adgey, J. (Jennifer) +9 more
core +4 more sources
Trombose de seio dural: relato de caso Dural sinus thrombosis: case report [PDF]
Arquivos de Neuro-Psiquiatria, 2006 Relata-se o caso de uma gestante de 24 anos, encaminhada ao serviço de neurologia por apresentar agitação, alucinações, confusão mental, cefaléia, perda de visão, afasia e convulsões.
Asdrubal Falavigna +2 more
doaj +3 more sources